Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBITDA Margin (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed EBITDA Margin for 12 consecutive years, with 237.43% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 25472.0% year-over-year to 237.43%, compared with a TTM value of 24.71% through Sep 2025, up 1371.0%, and an annual FY2024 reading of 23.03%, up 2351.0% over the prior year.
  • EBITDA Margin was 237.43% for Q3 2025 at CytomX Therapeutics, down from 0.64% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 49.52% in Q4 2024 and bottomed at 842.49% in Q4 2022.
  • Average EBITDA Margin over 5 years is 142.58%, with a median of 25.99% recorded in 2024.
  • The sharpest move saw EBITDA Margin plummeted -61514bps in 2021, then surged 84623bps in 2023.
  • Year by year, EBITDA Margin stood at 315.46% in 2021, then crashed by -167bps to 842.49% in 2022, then soared by 100bps to 3.74% in 2023, then skyrocketed by 1224bps to 49.52% in 2024, then plummeted by -579bps to 237.43% in 2025.
  • Business Quant data shows EBITDA Margin for CTMX at 237.43% in Q3 2025, 0.64% in Q2 2025, and 46.15% in Q1 2025.